Central Nervous System Toxicity in Prostate Cancer Patients Treated With Androgen Receptor Signaling Inhibitors: A Systematic Review, Meta-Analysis, and Network Meta-Analysis Publisher Pubmed



Matsukawa A^{1, 2} ; Yanagisawa T^{1, 2} ; Rajwa P^{1, 3} ; Fazekas T^{1, 4} ; Miszczyk M^{1, 5} ; Tsuboi I^{1, 6} ; Parizi MK^{1, 7} ; Laukhtina E^{1, 8} ; Klemm J^{1, 9} ; Chiujdea S^{1, 10} ; Mancon S^{1, 11} ; Mori K^{1, 2} ; Kimura S^{1, 2} ; Karakiewicz PI¹² Show All Authors Show Affiliations
Source: Clinical Genitourinary Cancer Published:2025

Abstract

Background: Androgen-receptor signaling inhibitors (ARSIs) significantly improve survival in systemic therapy for advanced/metastatic prostate cancer (PCa) patients; however possible central nervous system (CNS) toxicity is an unaddressed concern. We aimed to assess and compare the incidence of CNS-related adverse events (AEs) secondary to the treatment of PCa patients with different ARSIs. Materials: In August 2023, a comprehensive seach was conducted in three databases for randomized controlled trials (RCTs) of PCa patients receiving ARSIs plus ADT. The primary endpoints included mental impairment, cognitive impairment, seizure, fatigue, and falls. Results: Twenty-six RCTs, comprising 20,328 patients, were included in meta-analyses and network meta-analyses (NMAs). ARSIs increased the risk of mental impairment (RR: 1.72; 95% CI, 1.09-2.71), cognitive impairment (RR: 2.25; 95% CI, 1.78-2.86), seizure (RR: 2.20, 95% CI, 1.09-4.45), fatigue (RR: 1.31, 95% CI, 1.20-1.43), and falls (RR: 2.07, 95% CI, 1.60-2.67) compared to standard of care (SOC). Based on NMAs, Enzalutamide showed a significant increase in risk for all assessed CNS-related AEs, while Abiraterone demonstrated significant risk increases in cognitive impairment, fatigue, and falls. Conversely, Darolutamide did not exhibit significant increases in risk for any CNS-related AEs, except for fatigue. Conclusions: The addition of ARSIs to ADT increased all examined CNS-related AEs compared to SOC. Each ARSI is associated with a distinct profile of CNS-related AEs. Careful patient selection and monitoring for CNS sequelae is necessary to achieve the best quality of life in patients on ARSI + ADT for PCa. © 2024 The Author(s)